GLORIA-AF: Global Registry on Long-Term Oral Anti-thrombotic Treatment In Patients With Atrial Fibrillation (Phase II/III-India and Switzerland)

Trial Profile

GLORIA-AF: Global Registry on Long-Term Oral Anti-thrombotic Treatment In Patients With Atrial Fibrillation (Phase II/III-India and Switzerland)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 26 Sep 2017

At a glance

  • Drugs Dabigatran etexilate (Primary)
  • Indications Stroke; Thromboembolism
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms GLORIA-AF
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 26 Sep 2017 Results (n=2932) of part 2 assessing the predictors of dabigatran etexilate persistence over 2 years of follow-up in patients with newly diagnosed atrial fibrillation, published in the Journal of the American College of Cardiology.
    • 04 Dec 2016 The results were presented at the American Society of Hematology (ASH) Annual Meeting, as reported by Boehringer Ingelheim media release.
    • 04 Dec 2016 Results published in the Boehringer Ingelheim Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top